Full Press Release Details
| Jake Elguicze | ||
| Treasurer and Vice President of Investor Relations | ||
| 610-948-2836 |
TELEFLEX REPORTS THIRD QUARTER 2012 RESULTS
Revenues Rise 1.5% to $368.1 million; up 6.2% on Constant Currency Basis
GAAP Diluted EPS of $0.58
Adjusted Diluted EPS of $1.04
2012 Guidance Ranges
Updated for Constant Currency Revenue Growth and Adjusted EPS
Limerick, PA Teleflex Incorporated (NYSE: TFX)
today announced financial results for the third quarter ended September 30, 2012.
Third quarter 2012 net revenues were $368.1 million,
an increase of 1.5% over the prior year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues increased 6.2% over the prior year period.
Third quarter 2012 GAAP diluted earnings per share from continuing operations were $0.58, as compared to $0.80 in the prior year period. Third quarter 2012 adjusted diluted earnings per share from
continuing operations were $1.04, an increase of 4.0% over the prior year period.
Teleflex s strong 6.2% constant currency revenue
growth reflects increased volumes on a global basis, the positive contribution from recently introduced products to the marketplace, and our ability to raise the average selling price of our products by over one percent, said Benson Smith,
Chairman, President and CEO. In addition, our gross margin expanded seventy basis points from the year ago quarter, exceeding forty-nine percent. At the same time, we continued to invest in research and development and gained marketing
clearance for new vascular and anesthesia products during the quarter. Finally, we recently completed the acquisition of LMA International N.V., a global market leader in laryngeal masks.
Added Smith, With nine months of 2012, and the completion of the LMA acquisition behind us, we are updating our guidance ranges for constant
currency revenue growth and adjusted earnings per share. We now expect to generate constant currency revenue growth of between 6% and 7%, and adjusted earnings per share of between $4.35 and $4.40. We believe we are building momentum for a solid
finish to 2012 and into 2013 and beyond.
THIRD QUARTER NET REVENUE BY PRODUCT GROUP AND SEGMENT
Critical Care third quarter 2012 net revenues were $244.1 million, a decrease of 0.4% compared to the prior year period. Excluding the impact of foreign
currency fluctuations, third quarter 2012 net revenues increased 4.5% compared to the prior year period. The increase in revenue was due to higher sales of respiratory, urology, anesthesia and vascular access products.
Surgical Care third quarter 2012 net revenues were $69.6 million, an increase of 5.4% compared to the prior
year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues increased 10.1% compared to the prior year period. The increase in revenue was due to higher sales of ligation, closure and general surgical
instrument products, partially offset by a decline in sales of chest drainage products.
Cardiac Care third quarter 2012 net revenues were
$17.2 million, a decrease of 4.8% compared to the prior year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues increased 1.6% compared to the prior year period. The increase in revenue was due to higher
sales of intra-aortic balloon pumps, partially offset by a decline in sales of intra-aortic balloon catheters.
OEM and Development Services
( OEM ) third quarter 2012 net revenues were $36.9 million, an increase of 11.0% compared to the prior year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues increased 13.0% compared to the
prior year period. The increase in revenue was due to higher volume, higher capacity as a result of plant expansions, new products and price increases.
| Three Months Ended | % Increase/ (Decrease) | |||||||||||||||||||
| September 30, 2012 | September 25, 2011 | Constant Currency | Foreign Currency | Total Change | ||||||||||||||||
| (Dollars in millions) | ||||||||||||||||||||
| Critical Care | $ | 244.1 | $ | 245.2 | 4.5 | % | (4.9 | %) | (0.4 | %) | ||||||||||
| Surgical Care | 69.6 | 66.0 | 10.1 | % | (4.7 | %) | 5.4 | % | ||||||||||||
| Cardiac Care | 17.2 | 18.1 | 1.6 | % | (6.4 | %) | (4.8 | %) | ||||||||||||
| OEM | 36.9 | 33.2 | 13.0 | % | (2.0 | %) | 11.0 | % | ||||||||||||
| Other | 0.3 | 0.2 | 9.2 | % | (11.0 | %) | (1.8 | %) | ||||||||||||
| Total | $ | 368.1 | $ | 362.7 | 6.2 | % | (4.7 | %) | 1.5 | % |
During the third quarter of 2012, due to changes in the Company s management and internal reporting structure, the
Company s Latin American operations were moved from the Asia and Latin American Segment ( AJLA ) into the North American Segment. As a result of this change, the North American Segment is now referred to as the Americas Segment and
AJLA Segment is now referred to as the Asia Segment.
Americas third quarter 2012 net revenues were $169.7 million, an increase of 1.4%
compared to the prior year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues increased 1.7% compared to the prior year period. The increase in revenue was due to new product sales and price increases.
EMEA third quarter 2012 net revenues were $116.0 million, a decrease of 8.7% compared to the prior year period. Excluding the impact of
foreign currency fluctuations, third quarter 2012 net revenues increased 3.1% compared to the prior year period. The increase in revenue was due to higher volume, new product sales, and price increases.
Asia third quarter 2012 net revenues were $45.5 million, an increase of 29.8% compared to the prior year period. Excluding the impact of foreign currency
fluctuations, third quarter 2012 net revenues increased 32.1% compared to the prior year period. The increase in revenue was due to higher volume and price increases.
OEM third quarter 2012 net revenues were $36.9 million, an increase of 11.0% compared to the prior year period. Excluding the impact of foreign currency fluctuations, third quarter 2012 net revenues
increased 13.0% compared to the prior year period. The increase in revenue was due to higher volume, higher capacity as a result of plant expansions, new products and price increases.
| Three Months Ended | % Increase/ (Decrease) | |||||||||||||||||||
| September 30, 2012 | September 25, 2011 | Constant Currency | Foreign Currency | Total Change | ||||||||||||||||
| (Dollars in millions) | ||||||||||||||||||||
| Americas | $ | 169.7 | $ | 167.4 | 1.7 | % | (0.3 | %) | 1.4 | % | ||||||||||
| EMEA | 116.0 | 127.0 | 3.1 | % | (11.8 | %) | (8.7 | %) | ||||||||||||
| Asia | 45.5 | 35.1 | 32.1 | % | (2.3 | %) | 29.8 | % | ||||||||||||
| OEM | 36.9 | 33.2 | 13.0 | % | (2.0 | %) | 11.0 | % | ||||||||||||
| Total | $ | 368.1 | $ | 362.7 | 6.2 | % | (4.7 | %) | 1.5 | % |
Net revenues for the first nine months of 2012 were $1.132 billion, an increase of 3.9% compared to the prior year period. Excluding the impact of foreign currency fluctuations, net revenues for the first
nine months of 2012 increased 7.4% compared to the prior year period.
GAAP loss per share from continuing operations was ($5.22) for the
first nine months of 2012, as compared to diluted earnings per share of $1.88 in the prior year period. The financial results for the first nine months of 2012 reflect a goodwill impairment charge of $315.1 million, net of tax, or $7.72 per share,
incurred in the first quarter of 2012.
Adjusted diluted earnings per share from continuing operations for the first nine months of 2012 was
$3.26, an increase of 17.3% over the prior year period. This increase reflects additional sales volume and the introduction of new products to the marketplace, improved pricing, gross profit expansion, and reduced tax expense. The improvement in
profitability was partially offset by continuing investment in sales, marketing and research and development, and increased interest expense.
OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS
Depreciation and amortization of intangible assets, deferred financing costs and debt discount for the first nine months of 2012 were $69.2 million compared to $72.5 million for the prior year period.
Cash and cash equivalents at September 30, 2012 were $634.8 million compared to $584.1 million at December 31,
2011. On October 23, 2012, the Company acquired substantially all of the assets of LMA, a global provider of laryngeal masks with a portfolio of innovative products used extensively in anesthesia and emergency care. The Company paid $292.2
million in cash as initial consideration for the business. On October 23, 2012, in a separate transaction, the Company also acquired the LMA branded laryngeal mask supraglottic airway business and certain other products in the United Kingdom,
Ireland and Channel Islands from the shareholders of Intravent Direct Limited and affiliates for $19.9 million in cash. These acquisitions complement the anesthesia product portfolio in the Company s Critical Care division.
Net accounts receivable at September 30, 2012 were $266.9 million compared to $286.2 million at December 31, 2011.
Net inventories at September 30, 2012 were $295.6 million compared to $298.8 million at
Net debt obligations at September 30, 2012 were $394.9 million compared to $445.9 million at December 31,
Including the recently completed acquisitions of LMA International N.V. and affiliates, the Company s financial estimates for 2012 are as follows:
Constant currency revenue growth between 6% and 7% for full year 2012. This compares to the Company s prior expectation of constant
currency revenue growth between 4% and 6% for full year 2012.
Adjusted diluted earnings per share in the range of $4.35 to $4.40. This
compares to the Company s prior expectation of adjusted diluted earnings per share in the range of $4.25 to $4.45.
EARNINGS PER SHARE RECONCILIATION
| Low | High | |||||||
| Loss per share attributable to common shareholders | ($ | 4.58 | ) | ($ | 4.53 | ) | ||
| Goodwill impairment, net of tax | $ | 7.72 | $ | 7.72 | ||||
| Special items, net of tax | $ | 0.35 | $ | 0.35 | ||||
| Intangible amortization expense, net of tax | $ | 0.70 | $ | 0.70 | ||||
| Amortization of debt discount on convertible notes, net of tax | $ | 0.16 | $ | 0.16 | ||||
| Adjusted diluted earnings per share | $ | 4.35 | $ | 4.40 |
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company s website
at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until November 7, 2012, 11:59pm (ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International),
Constant currency revenue and growth exclude the impact of translating the results of international subsidiaries at different currency exchange rates from period to period.
Certain financial information is presented on a rounded basis, which may cause minor differences.
Product group results and commentary exclude the impact of discontinued operations, items included in restructuring and impairment charges, and losses
and other charges set forth in the condensed consolidated statements of income.
NOTES ON NON-GAAP FINANCIAL MEASURES
This press release includes certain non-GAAP financial measures. These measures include (i) adjusted diluted earnings per share, which excludes, depending on the period presented, the effect of
charges associated with a goodwill impairment, our restructuring programs and asset impairments, losses and other charges related to acquisition costs, gain on sale of businesses and assets, refinancing transactions and costs associated with
severance payments and benefits to be provided to our former chief executive officer, charges associated with the amortization of additional interest expense related to an interest rate swap terminated in 2011, intangible amortization expense, the
amortization of debt discount on convertible notes and certain tax adjustments relating to the resolution of various tax matters relating to prior years; and (ii) constant currency revenue and growth, which exclude the impact of translating the
results of international subsidiaries at different currency exchange rates from period to period. Consistent with past practice, adjusted diluted earnings per share has not been adjusted to exclude the benefit resulting from the forfeiture of equity
awards. Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex s day-to-day operations. In addition, management uses these financial measures for internal managerial purposes, when
publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as
a substitute for GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are set forth below. This press release also includes forecasted constant currency revenue growth, which is also a
non-GAAP measure. A reconciliation of forecasted constant currency revenue growth to GAAP forecasted growth has not been provided as management is unable to forecast trends in foreign currency exchange rates.
RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS
| Three Months Ended September 30, 2012 | Three Months Ended September 25, 2011 | |||||||
| (Dollars in thousands, except per share) | ||||||||
| Income and diluted earnings per share attributable to common | $ | 24,263 | $ | 32,632 | ||||
| shareholders | $ | 0.58 | $ | 0.80 | ||||
| Restructuring and impairment charges | 1,087 | |||||||
| Tax benefit | (412 | ) | ||||||
| Restructuring and impairment charges, net of tax | 675 | |||||||
| $ | 0.02 | |||||||
| Losses and other charges(A) | 9,862 | |||||||
| Tax benefit | (1,503 | ) | ||||||
| Losses and other charges, net of tax | 8,359 | |||||||
| $ | 0.20 | |||||||
| Early termination of interest rate swap(B) | 3,662 | |||||||
| Tax benefit | (1,347 | ) | ||||||
| Early termination of interest rate swap, net of tax | 2,315 | |||||||
| $ | 0.06 | |||||||
| Amortization of debt discount on convertible notes | 2,651 | 2,455 | ||||||
| Tax benefit | (965 | ) | (892 | ) | ||||
| Amortization of debt discount on convertible notes, net of tax | 1,686 | 1,563 | ||||||
| $ | 0.04 | $ | 0.04 | |||||
| Intangible amortization expense | 11,061 | 10,712 | ||||||
| Tax benefit | (4,029 | ) | (3,914 | ) | ||||
| Intangible amortization expense, net of tax | 7,032 | 6,798 | ||||||
| $ | 0.17 | $ | 0.17 | |||||
| Tax adjustments(C) | (1,303 | ) | ||||||
| $ | (0.03 | ) | ||||||
| Adjusted income and diluted earnings per share | $ | 43,027 | $ | 40,993 | ||||
| $ | 1.04 | $ | 1.00 |
RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS
| Nine Months Ended September 30, 2012 | Nine Months Ended September 25, 2011 | |||||||
| (Dollars in thousands, except per share) | ||||||||
| (Loss)/income and (basic)/diluted earnings per share attributable to | $ | (213,097 | ) | $ | 76,749 | |||
| shareholders | $ | (5.22 | ) | $ | 1.88 | |||
| Goodwill impairment | 332,128 | |||||||
| Tax benefit | (16,983 | ) | ||||||
| Goodwill impairment, net of tax | 315,145 | |||||||
| $ | 7.72 | |||||||
| Restructuring and impairment charges | 84 | 710 | ||||||
| Tax charge / (benefit) | 61 | (250 | ) | |||||
| Restructuring and impairment charges, net of tax | 145 | 460 | ||||||
| $ | 0.00 | $ | 0.01 | |||||
| Losses and other charges(A) | 10,142 | 20,913 | ||||||
| Tax benefit | (1,726 | ) | (7,601 | ) | ||||
| Losses and other charges, net of tax | 8,416 | 13,312 | ||||||
| $ | 0.21 | $ | 0.33 | |||||
| Early termination of interest rate swap(B) | 11,056 | |||||||
| Tax benefit | (4,024 | ) | ||||||
| Early termination of interest rate swap, net of tax | 7,032 | |||||||
| $ | 0.17 | |||||||
| Amortization of debt discount on convertible notes | 7,787 | 7,212 | ||||||
| Tax benefit | (2,835 | ) | (2,621 | ) | ||||
| Amortization of debt discount on convertible notes, net of tax | 4,952 | 4,591 | ||||||
| $ | 0.12 | $ | 0.11 | |||||
| Intangible amortization expense | 32,263 | 32,087 | ||||||
| Tax benefit | (11,766 | ) | (11,697 | ) | ||||
| Intangible amortization expense, net of tax | 20,497 | 20,390 | ||||||
| $ | 0.50 | $ | 0.50 | |||||
| Tax adjustments(C) | (8,957 | ) | (2,165 | ) | ||||
| $ | (0.22 | ) | $ | (0.05 | ) | |||
| Anti-dilutive effect on EPS(D) | $ | (0.03 | ) | |||||
| Adjusted income and diluted earnings per share | $ | 134,133 | $ | 113,337 | ||||
| $ | 3.26 | $ | 2.78 |
RECONCILIATION OF NET DEBT OBLIGATIONS
| September 30, 2012 | December 31, 2011 | |||||||
| (Dollars in thousands) | ||||||||
| Note payable and current portion of long-term borrowings | $ | 4,700 | $ | 4,986 | ||||
| Long term borrowings | 962,596 | 954,809 | ||||||
| Unamortized debt discount | 62,404 | 70,191 | ||||||
| Total debt obligations | 1,029,700 | 1,029,986 | ||||||
| Less: cash and cash equivalents | 634,829 | 584,088 | ||||||
| Net debt obligations | $ | 394,871 | $ | 445,898 |
ABOUT TELEFLEX INCORPORATED
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve
outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,100 people worldwide and serves healthcare providers in more than 130 countries. For additional information about Teleflex please
refer to www.teleflex.com.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but not limited to, forecasted 2012 constant currency revenue growth and adjusted
earnings per share. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales
growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance